NK Cell Therapy Pipeline Insight 2021 by DelveInsight

June 25 23:30 2021

NK Cell Therapy Pipeline” report has been added to DelveInsight

 

NK Cell Therapy: Overview

Natural Killer (NK) Cells are recognized for their ability to kill cancerous cells. These are lymphocytes hailing from the same family as that of T and B cells, however, NK cells are classified as group I Innate Lymphocytes (ILCs) and respond quickly to a wide variety of conditions including cancer.

 

NK Cell Therapy: Function

Natural killer (NK) cells are granular lymphocytes that play important roles in immunity against viruses and in the immune surveillance of tumors. In addition to being a potent innate source of IFN-γ, NK cells hold cytoplasmic granula that contain perforin and granzymes involved in cell-mediated cytotoxicity.

 

NK Cell Therapy Pipeline

DelveInsight’s, “NK Cell Therapy – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

NK Cell Therapy Pipeline: Key Players

  • Nantkwest
  • Coronado Biosciences
  • Artiva Biotherapeutics
  • Affimed
  • Bristol-Myers Squibb
  • Celularity Incorporated
  • ZIOPHARM Oncology
  • Surface Oncology
  • Sorrento Therapeutics
  • AvidBiotic Corporation
  • And many others

 

NK Cell Therapy Pipeline: Report

NK Cell Therapy: NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK Cell Therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells.

 

NK Cell Therapy Pipeline: Emerging Drugs Chapters

This segment of the NK Cell Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

NK Cell Therapy Emerging Drugs

 

haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest

NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio’s IL-15 superagonist for the treatment of advanced refractory metastatic Merkel cell carcinoma. The therapy leverages the company’s hANK Cell Platform. The drug is in Phase II of clinical development.

 

Request free sample copy- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight

 

Table of Content

  • Introduction
  • Executive Summary
  • NK Cell Therapy: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • NK Cell Therapy – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • NK Cell Therapy Collaboration Deals
  • Late Stage Products (Pre-registration)
  • Drug name: Company name
  • Mid Stage Products (Phase II)
  • Avelumab; N-803; haNK: NantKwest
  • Early Stage Products (Phase I)
  • CNDO-109-AANK Cells: Coronado Biosciences
  • Pre-clinical and Discovery Stage Products
  • Drug name: Company name
  • Inactive Products
  • NK Cell Therapy Key Companies
  • NK Cell Therapy Key Products
  • NK Cell Therapy- Unmet Needs
  • NK Cell Therapy- Market Drivers and Barriers
  • NK Cell Therapy- Future Perspectives and Conclusion
  • NK Cell Therapy Analyst Views
  • NK Cell Therapy Key Companies
  • Appendix

 

NK Cell Therapy Pipeline: Report Insights

  • NK Cell Therapy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

 

NK Cell Therapy Pipeline: Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

 

What are the NK Cell Therapy Report Highlights?

  • The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell Therapy R&D. The therapies under development are focused on novel approaches for NK Cell Therapy.
  • A global increase in Cancer incident cases and relapses has led to an inclination towards Novel effective treatments such as adjuvant therapy drugs, and NK cell therapies.

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/